Host Determinants of Immune Checkpoint Inhibitor Efficacy: Immune, Genetic, Metabolic, and Lifestyle Factors
International Journal of Molecular Sciences · 08.05.2026 · 27 (10) · 4178
DOI: 10.3390/ijms27104178 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.05.2026. Verfasst von Ali Awada und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by enhancing antitumor immune responses; however, clinical outcomes remain highly variable across patients and tumor types. While tumor-intrinsic factors such as PD-L1 expression and tumor mutational burden provide some predictive value, they do not fully explain response heterogeneity. Increasing evidence highlights the critical role of host-related determinants in modulating ICI efficacy. This review provides a comprehensive overview of key host factors, including baseline immune competence, T-cell repertoire diversity, cytokine profiles, and peripheral biomarkers. It further examines the impact of germline genetics, HLA genotype, and epigenetic regulation on immune responses. The role of the gut microbiome and its metabolites is explored, alongside the impact of metabolic status, obesity, nutrition, and lifestyle behaviors. Additionally, the effects of co-medications and comorbidities are discussed. Integrating these host-related factors may improve patient stratification and support the development of personalized immunotherapy strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon.
- Faculty of Medicine and Medical Sciences, University of Balamand, Tripoli P.O. Box 100, Lebanon.
- Department of Diagnostic Radiology, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon.
ORCID-Profile: Nicole Charbel, Andrea Issa, Wajih Nasr, Sara El Meski, Ali Tarhini, Firas Kreidieh
Zitieren
APA
Awada, A., Charbel, N., Faraj, S., Hassan, M., Awada, D., Issa, A., Nasr, W., El Meski, S., Hatahet, Z., Tarhini, A., Rizkallah, J., & Kreidieh, F. (2026). Host Determinants of Immune Checkpoint Inhibitor Efficacy: Immune, Genetic, Metabolic, and Lifestyle Factors. International Journal of Molecular Sciences, 27(10), 4178. https://doi.org/10.3390/ijms27104178
Vancouver
Awada A, Charbel N, Faraj S, Hassan M, Awada D, Issa A, et al. Host Determinants of Immune Checkpoint Inhibitor Efficacy: Immune, Genetic, Metabolic, and Lifestyle Factors. International Journal of Molecular Sciences. 2026;27(10):4178. doi:10.3390/ijms27104178
BibTeX
@article{Awada2026,
author = {Awada, Ali and Charbel, Nicole and Faraj, Sary and Hassan, Mohammad and Awada, Duha and Issa, Andrea and Nasr, Wajih and El Meski, Sara and Hatahet, Zuhair and Tarhini, Ali and Rizkallah, Joe and Kreidieh, Firas},
title = {Host Determinants of Immune Checkpoint Inhibitor Efficacy: Immune, Genetic, Metabolic, and Lifestyle Factors},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {10},
pages = {4178},
doi = {10.3390/ijms27104178}
}
EUVIMED